Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Evaluation of the anxiolytic-like profile of the GABAB receptor positive modulator CGP7930 in rodents.

Jacobson LH, Cryan JF.

Neuropharmacology. 2008 Apr;54(5):854-62. doi: 10.1016/j.neuropharm.2008.01.004. Epub 2008 Jan 13.

PMID:
18328507
2.

CGP7930: a positive allosteric modulator of the GABAB receptor.

Adams CL, Lawrence AJ.

CNS Drug Rev. 2007 Fall;13(3):308-16. Review.

3.

Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site.

Atack JR.

Curr Drug Targets CNS Neurol Disord. 2003 Aug;2(4):213-32. Review.

PMID:
12871032
4.

GABA-A receptors: a viable target for novel anxiolytics?

Whiting PJ.

Curr Opin Pharmacol. 2006 Feb;6(1):24-9. Epub 2005 Dec 15. Review.

PMID:
16359919
5.

Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.

Zwanzger P, Rupprecht R.

J Psychiatry Neurosci. 2005 May;30(3):167-75. Review.

6.

A Systematic Review of the Anxiolytic-Like Effects of Essential Oils in Animal Models.

de Sousa DP, de Almeida Soares Hocayen P, Andrade LN, Andreatini R.

Molecules. 2015 Oct 14;20(10):18620-60. doi: 10.3390/molecules201018620. Review.

7.

GABAB receptors in reward processes.

Vlachou S, Markou A.

Adv Pharmacol. 2010;58:315-71. doi: 10.1016/S1054-3589(10)58013-X. Review.

PMID:
20655488
8.

Molecular mechanisms of GABA(B) receptor activation: new insights from the mechanism of action of CGP7930, a positive allosteric modulator.

Binet V, Goudet C, Brajon C, Le Corre L, Acher F, Pin JP, Prézeau L.

Biochem Soc Trans. 2004 Nov;32(Pt 5):871-2. Review.

PMID:
15494037
9.

GABAB receptors as a therapeutic strategy in substance use disorders: focus on positive allosteric modulators.

Filip M, Frankowska M, Sadakierska-Chudy A, Suder A, Szumiec L, Mierzejewski P, Bienkowski P, Przegaliński E, Cryan JF.

Neuropharmacology. 2015 Jan;88:36-47. doi: 10.1016/j.neuropharm.2014.06.016. Epub 2014 Jun 24. Review.

PMID:
24971600
10.

Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

Licata SC, Rowlett JK.

Pharmacol Biochem Behav. 2008 Jul;90(1):74-89. doi: 10.1016/j.pbb.2008.01.001. Epub 2008 Jan 12. Review.

11.

[GABAB receptor as therapeutic target for drug addiction: from baclofen to positive allosteric modulators].

Agabio R, Colombo G.

Psychiatr Pol. 2015 Mar-Apr;49(2):215-23. doi: 10.12740/PP/33911. Review. Polish.

12.

Animal models of anxiety: an ethological perspective.

Rodgers RJ, Cao BJ, Dalvi A, Holmes A.

Braz J Med Biol Res. 1997 Mar;30(3):289-304. Review.

PMID:
9246227
13.

Animal models for screening anxiolytic-like drugs: a perspective.

Bourin M.

Dialogues Clin Neurosci. 2015 Sep;17(3):295-303. Review.

14.
15.

New directions in anxiolytic drug research.

Scott MK, Demeter DA, Nortey SO, Dubinsky B, Shank RP, Reitz AB.

Prog Med Chem. 1999;36:169-200. Review.

PMID:
10818673
16.

50 years of hurdles and hope in anxiolytic drug discovery.

Griebel G, Holmes A.

Nat Rev Drug Discov. 2013 Sep;12(9):667-87. doi: 10.1038/nrd4075. Review.

17.

The age of anxiety: role of animal models of anxiolytic action in drug discovery.

Cryan JF, Sweeney FF.

Br J Pharmacol. 2011 Oct;164(4):1129-61. doi: 10.1111/j.1476-5381.2011.01362.x. Review.

18.

Pharmacogenetics of anxiolytic drugs.

Tiwari AK, Souza RP, Müller DJ.

J Neural Transm (Vienna). 2009 Jun;116(6):667-77. doi: 10.1007/s00702-009-0229-6. Epub 2009 May 12. Review.

PMID:
19434367
19.
20.

Dietary and botanical anxiolytics.

Alramadhan E, Hanna MS, Hanna MS, Goldstein TA, Avila SM, Weeks BS.

Med Sci Monit. 2012 Apr;18(4):RA40-8. Review.

Supplemental Content

Support Center